In this poster, we show that Ulti-HEP offers a superior in vitro liver model compared to HepG2 cells, with greater liver functionality that is comparable to primary human hepatocytes. These data alongside the expansion capacity and amenability of Ulti-HEP using CRISPR-based gene editing showcase the spectrum of opportunities iPSC-derived hepatocytes can offer in the fields of disease modelling, large-scale drug screening, genotoxicity, and hepatic safety.
